Skip to main content
. 2023;24(6):1963–1969. doi: 10.31557/APJCP.2023.24.6.1963

Table 1.

Baseline Characteristics of Patients Received DeVIC Therapy (n=36)

N=36
Sex, number (%) Male 16 (44)
Female 20 (56)
Age (years), median (IQR) 72 (64-75)
Treatment line, number (%) First line 3 (8)
Second line or more 33 (92)
Dose (mg/m2), median (IQR) Ifosfamide 1,192 (1,089-1,414)
Etoposide 81 (73-98)
Carboplatine 238 (218-295)
Body surface area (m2), median (IQR) 1.53 (1.44-1.68)
Renal function before administration, median (IQR) Ccr (mL/min) 56 (45-68)
Blood cell count before administration, median (IQR) Neutrophil (×103 /μL) 3.58 (2.80-4.81)
Hemoglobin (μg/dL) 11.1 (9.9-11.9)
Platelet (×104 /μL) 21.7 (15.3-31.6)

Abbreviation: interquartile range; IQR, creatinine clearance; Ccr